Physician profile
Lawrence Dodd
NPI 1932173457
$1,179.14
in general payments reported to CMS, 2019-2025
15 companies · $57.75 in 2025
The $57.75 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $25.53 · 2021: $83.91 · 2022: $104 · 2023: $168 · 2024: $36.86 · 2025: $57.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $561.65 | 2019 | |
| Medical Device Business Services, INC. | $126.05 | 2019 | |
| Djo, LLC | $121.69 | 2021-2025 | Cmf |
| Heron Therapeutics, INC. | $65.74 | 2023 | Zynrelef |
| Innovation Technologies INC | $48.06 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $41.93 | 2022-2023 | Zilretta, Iovera, Exparel |
| Horizon Therapeutics Plc | $38.76 | 2021-2022 | |
| Davol INC. | $37.41 | 2025 | Arista |
| Pacira Therapeutics, INC. | $25.53 | 2020 | |
| Novo Nordisk INC | $25.00 | 2021 | |
| Bioventus LLC | $21.59 | 2023 | Durolane |
| Inspire Medical Systems, INC. | $18.51 | 2024 | Inspire |
| Vertex Pharmaceuticals Incorporated | $18.35 | 2024 | |
| Smith+Nephew, INC. | $15.09 | 2019 | |
| Abbvie INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.